Ann: Company Update - Presentation, page-2

Good to see an expected date for first patient enrolment.

18month timeframe is a long runway though, however the sales trajectory of TR PRO+ and the added launch in 2025 with the additional indications could prove to be a solid revenue generator to mitigate the need for additional capital. Phase 3 trials are expensive so the risk now is funding for Phase 3 activities. Ramp of of sales reps and territory managers will eat more of the cash on hand, how quickly can they scale TR PRO+ is the million dollar question.

For now I have taken a profit and exited my position after holding for 12months, will look for re-entry closer to Phase3 read out dates.
Good luck guys.